TY - JOUR
T1 - Local and Systemic Adverse Reactions to mRNA COVID‐19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID‐19 Infection.
AU - Pares Badell, Oleguer
AU - Martinez Gomez, Javier
AU - Pinós Tella, Laia
AU - Borras Bermejo, Blanca
AU - Uriona Tuma, Sonia Maria
AU - Otero Romero, Susana Isabel
AU - Rodrigo Pendas, Jose Angel
AU - Cosio-Gil, Y
AU - Agusti Escasany, M. Antonieta
AU - Aguilera Martin, , C
AU - Campins, M
N1 - Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
PY - 2021/12/10
Y1 - 2021/12/10
N2 - The aim of this study was to assess adverse reactions to COVID-19 vaccines, comparing the BNT162b2 or the mRNA-1273 COVID-19 vaccines and the presence and seriousness of a previous COVID-19 infection. We conducted a cross-sectional online survey of vaccinated healthcare workers at a tertiary hospital in Barcelona (Spain). Thirty-eight percent of vaccine recipients responded to the questionnaire. We compared the prevalence of adverse reactions by vaccine type and history of COVID-19 infections. A total of 2373 respondents had received the BNT162b2 vaccine, and 506 the mRNA-1273 vaccine. The prevalence of at least one adverse reaction with doses 1 and 2 was 41% and 70%, respectively, in the BNT162b2 group, and 60% and 92% in the mRNA-1273 group (p < 0.001). The BNT162b2 group reported less prevalence of all adverse reactions. Need for medical leave was significantly more frequent among the mRNA-1273 group (12% versus 4.6% p < 0.001). Interestingly, respondents with a history of allergies or chronic illnesses did not report more adverse reactions. The frequency of adverse reactions with dose 2 was 96% (95% CI 88-100%) for those with a history of COVID-19 related hospitalization, and 86% (95% CI 83-89%) for those with mild or moderate symptomatic COVID-19, significantly higher than for participants with no history of COVID-19 infections (67%, 95% CI 65-69%). Our results could help inform vaccine recipients of the probability of their having adverse reactions to COVID-19 vaccines.
AB - The aim of this study was to assess adverse reactions to COVID-19 vaccines, comparing the BNT162b2 or the mRNA-1273 COVID-19 vaccines and the presence and seriousness of a previous COVID-19 infection. We conducted a cross-sectional online survey of vaccinated healthcare workers at a tertiary hospital in Barcelona (Spain). Thirty-eight percent of vaccine recipients responded to the questionnaire. We compared the prevalence of adverse reactions by vaccine type and history of COVID-19 infections. A total of 2373 respondents had received the BNT162b2 vaccine, and 506 the mRNA-1273 vaccine. The prevalence of at least one adverse reaction with doses 1 and 2 was 41% and 70%, respectively, in the BNT162b2 group, and 60% and 92% in the mRNA-1273 group (p < 0.001). The BNT162b2 group reported less prevalence of all adverse reactions. Need for medical leave was significantly more frequent among the mRNA-1273 group (12% versus 4.6% p < 0.001). Interestingly, respondents with a history of allergies or chronic illnesses did not report more adverse reactions. The frequency of adverse reactions with dose 2 was 96% (95% CI 88-100%) for those with a history of COVID-19 related hospitalization, and 86% (95% CI 83-89%) for those with mild or moderate symptomatic COVID-19, significantly higher than for participants with no history of COVID-19 infections (67%, 95% CI 65-69%). Our results could help inform vaccine recipients of the probability of their having adverse reactions to COVID-19 vaccines.
KW - SARS-CoV-2
KW - COVID-19-vaccination
KW - mRNA vaccines
KW - Adverse reactions
KW - Healthcare workers
KW - SARS-CoV-2
KW - COVID-19-vaccination
KW - mRNA vaccines
KW - Adverse reactions
KW - Healthcare workers
KW - SARS-CoV-2
KW - COVID-19-vaccination
KW - mRNA vaccines
KW - Adverse reactions
KW - Healthcare workers
U2 - 10.3390/vaccines9121463
DO - 10.3390/vaccines9121463
M3 - Article
SN - 2076-393X
VL - 9
JO - Vaccines
JF - Vaccines
IS - 12
M1 - 1463
ER -
